NCT01723254View on ClinicalTrials.gov

A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis

PHASE1CompletedINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Allergic Rhinitis
Interventions
BIOLOGICAL

IGE-1

Intramuscular, multiple dose

BIOLOGICAL

IGE-2

Intramuscular, multiple dose

BIOLOGICAL

Saline

Saline (0.9% sodium chloride)

Trial Locations (4)

K1Y 4G2

Ottawa Allergy Research Corporation, Ottawa

H4N 3C5

Diex Research Montreal Inc., Montreal

G1V 4M6

Centre de Recherche Appliquee en Allergie de Quebec, Québec

J1H 1Z1

Diex Research Sherbrooke Inc., Sherbrooke

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01723254 - A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis | Biotech Hunter | Biotech Hunter